Pregabalin Capsule
Product Images NDC 70518-3636

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-3636). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Pregabalin 50 mg capsules, quantity of 90 capsules, manufactured by Ascend Labs, LLC, and repackaged by RemedyRepack Inc. The label includes the NDC 70518-3636 and storage instructions, along with a barcode and a QR code.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

This image shows a mathematical formula used for calculating creatinine clearance (CLCr), factoring in patient age, weight, serum creatinine levels, and an adjustment for female patients. The formula is relevant to pharmacokinetic considerations in dosing Pregabalin capsules by RemedyRepack Inc.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar graph titled Study E1 and Study E3 showing responder rates (%) for different dosages of Pregabalin compared to placebo. The vertical axis represents responder rates from 0% to 60%. Study E1 includes placebo, 50, 150, 300, and 600 mg/day dosages, with statistical significance indicated by asterisks on 150 mg/day and higher doses. Study E3 includes placebo, 600 mg/day BID, and 600 mg/day TID doses, also showing significant response rates for treated groups compared to placebo. Sample sizes (N) are listed below each category.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph depicting seizure reduction as median percentage change from baseline versus pregabalin dose (mg/day) across multiple studies. The graph shows increasing seizure reduction with higher doses up to 600 mg/day, with different symbols representing Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID regimens. Significant p-values are noted for dose comparisons with placebo.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph showing the percent of patients improved relative to the percent improvement in pain from baseline. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The vertical axis represents the percent of patients improved, and the horizontal axis represents percent improvement in pain from baseline.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph comparing the percent of subjects improved over a range of percentage improvements from baseline to Week 12 BOCF for two groups: Pregabalin and Placebo. The y-axis represents the percent of subjects improved, and the x-axis shows percent improvement from baseline, with vertical lines marking specific percentage thresholds.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph showing percent of subjects improved on the y-axis versus percent improved from baseline to Week 16 on the x-axis, comparing Pregabalin and Placebo. The graph features two curves, with Pregabalin showing a higher percent improvement than Placebo throughout the range.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day and placebo. The vertical axis shows percent of patients improved (0-100%), and the horizontal axis displays percent improvement in pain from baseline (0-100%).*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line chart depicting percent improvement in pain from baseline over time. The graph compares four groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and Placebo, showing trends in patient improvement percentages across a 100-day period.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph illustrating the percent of patients improved against percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing varying levels of pain improvement across these groups.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The vertical axis shows the percent of patients improved, and the horizontal axis shows percent improvement in pain.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg, as well as a placebo group. The graph shows trends of patient improvement across different pain reduction percentages.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A survival curve chart comparing the estimated percentage of subjects without LTR (loss to remission) over 180 days for Pregabalin and placebo groups. The chart shows Pregabalin maintains a higher percentage of subjects without LTR compared to placebo across the timeline.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure diagram of pregabalin showing its molecular arrangement with amino (NH2) and carboxylic acid (CO2H) functional groups attached to a carbon backbone.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.